Contact Us | News |  Site Map

Aridis Pharmaceuticals  © 2010   Le3 Web Designs

Privacy Policy

Monoclonal antibodies (mAb) against infectious disease targets are recently gaining significant interests, due to the strong safety track record of mAbs in humans and the lower risks of drug resistance.

Aerucin represents a fundamentally new immunological approach to treat infections with P. aeruginosa (Pa), a pervasive gram negative bacteria that is increasingly resistant to multiple drugs. Aerucin is a fully human monoclonal IgG1 antibody that binds to alginate, a widely distributed cell surface polysaccharide on Pa, and marks the bacterium for phagocytic ingestion and destruction by the immmune system. Aerucin offers a unique opportunity to circumvent the pervasive problems of antibiotic resistance associated with current antibiotic therapies.

There is extensive in vitro data demonstrating Aerucin's effectiveness in phagocytic killing of a wide range of both mucoid and non-mucoid clinical isolates of Pa, including current antibiotic resistant strains from pneumonia and CF patients. Aerucin protects mice from lethal challenges with a variety of Pa strains in the acute pneumonia model, protects against eye infections in a keratitis model, and protects against systemic sepsis infection model. These studies support the therapeutic and prophylactic uses of Aerucin to a broad range of Pa infections.